Luciana Prats Branco1, Tarso Adoni2, Samira Luisa Apostolos-Pereira3, Joseph Bruno Bidin Brooks1, Eber Castro Correa4, Carlos Augusto Damasceno5, Audred Cristina Biondo Eboni6, Leticia Fezer7, Paulo Diniz da Gama8, Marcus Vinicius Magno Goncalves6, Sidney Gomes9,10, Anderson Kuntz Grzesiuk11, Maria Fernanda Mendes3, Rogerio Rizo Morales12, Andre Muniz13, Monica Fiuza Koncke Parolin14, Maria Lucia Vellutini Pimentel7, Marlise de Castro Ribeiro15, Gutemberg Augusto Cruz Dos Santos16, Henry Koiti Sato17, Simone Batista Scherpenhuijzen18, Claudio Scorcine1, Fabio Siquineli19, Nise Alexandra de Carvalho Sousa20, Daniel Lima Varela21, Tereza Cristina Avila Winckler22, Yara Dadalti Fragoso1. 1. Universidade Metropolitana de Santos, Departamento de Neurologia, São Paulo SP, Brasil. 2. Hospital Sírio Libanês de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil. 3. Universidade de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil. 4. Clínica de Neurologia e Endocrinologia, Departamento de Neurologia, Brasília DF, Brasil. 5. Universidade Federal de Juiz de Fora, Departamento de Neurologia, Juiz de Fora MG, Brasil. 6. Universidade da Região de Joinville, Departamento de Neurologia, Joinville SC, Brasil. 7. Santa Casa da Misericórdia do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil. 8. Pontificia Universidade Católica Sorocaba, Departamento de Neurologia, Sorocaba SP, Brasil. 9. Hospital Beneficencia Portuguesa, Departamento de Neurologia, São Paulo SP, Brasil. 10. Hospital Paulistano, Departamento de Neurologia, São Paulo SP, Brasil. 11. Clínica Neurológica, Cuiabá MT, Brasil. 12. Universidade Federal de Uberlandia, Departamento de Neurologia, Uberlândia MG, Brasil. 13. Hospital da Bahia, Departamento de Neurologia, Salvador BA, Brasil. 14. Clínica Neurológica, Curitiba PR, Brasil. 15. Universidade Federal de Ciências da Saúde de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brasil. 16. Universidade Estacio de Sá, Departamento de Neurologia, Rio de Janeiro RJ, Brasil. 17. Instituto de Neurologia de Curitiba, Departamento de Neurologia, Curitiba PR, Brasil. 18. Universidade Federal do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil. 19. Universidade Regional de Blumenau, Departamento de Neurologia, Blumenau SC, Brasil. 20. Universidade Hospital Getúlio Vargas, Departamento de Neurologia, Manaus AM, Brasil. 21. Serviço de Neurologia e Neurocirurgia de Passo Fundo, Passo Fundo RS, Brasil. 22. Universidade Positivo, Departamento de Neurologia, Curitiba PR, Brasil.
Abstract
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). OBJECTIVE: To identify the serologic profile of JCV in patients with MS. METHODS: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. RESULTS: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. CONCLUSION: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). OBJECTIVE: To identify the serologic profile of JCV in patients with MS. METHODS: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. RESULTS: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. CONCLUSION: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
Authors: Robert Bonek; Wojciech Guenter; Robert Jałowiński; Anna Karbicka; Anna Litwin; Maciej Maciejowski; Radosław Zajdel; Karolina Zajdel; Veronique Petit; Konrad Rejdak Journal: J Clin Med Date: 2021-05-06 Impact factor: 4.241